Armata Pharmaceuticals develops new synthetic phage candidate set for INDA in Q4
Armata Pharmaceuticals has developed a new synthetic phage candidate targeting the pathogen Pseudomonas aeruginosa to treat serious respiratory infections, with an emphasis on cystic fibrosis patients. The candidate, known as AP-PA02, is being developed as a replacement for AP-PA01, which was recently featured in the peer-reviewed journal Infection following the successful treatment of a multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient. AP-PA02 demonstrated broad coverage against approximately 90% of tested Pseudomonas isolates, providing strong rationale for expedited development. Manufacturing of clinical trial material is underway to support filing of an Investigational New Drug Application with the FDA in Q4. In addition, Armata intends to file a clinical trial application with the relevant competent authority in Europe to initiate a clinical trial evaluating safety and tolerability of AP-PA02 in cystic fibrosis patients chronically infected with P. aeruginosa.